Navigation Links
Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors

IRVINE, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products used in the treatment of patients suffering from severe angina, today announced the addition of veteran medical device executive and an experienced public company director, Raymond W. Cohen as a member of the Company's Board of Directors, increasing the number of board members to six.

Mr. Cohen, 49, has over 25 years of executive experience in the medical technology field and is currently the Chief Executive Officer and a member of the Board of Directors of Symphony Medical Inc., a venture-capital backed developer of novel biotherapeutic therapies to treat heart failure and other cardiac abnormalities.

For the decade prior to 2006, Cohen served as Chairman and CEO of publicly traded Cardiac Science, Inc. having served in that role during the period of rapid revenue growth and through the company's merger with Quinton Cardiology in late 2005. Today Cardiac Science is a leading manufacturer of automated public-access defibrillators and diagnostic cardiology systems, generating over $200 million in annual revenue. Cohen continues to serve on the board of Cardiac Science and also serves on the boards of BioLife Solutions, Inc., a publicly traded company, and BioGenex, Inc., and Syncroness, Inc.

Paul J. McCormick, the Company's Chairman of the Board commented, "Mr. Cohen has a solid track record of success in developing and commercializing innovative medical technology, particularly in the cardiovascular market. He brings the vision, insight and skills necessary to make a significant contribution to the Cardiogenesis Board of Directors and our shareholders. We are very pleased to have Mr. Cohen join our board and look forward to working with him."

About Cardiogenesis Corporation

Cardiogenesis specializes in providing surgical devices to treat cardiovascular disease and severe angina. The Company's market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a procedure known as Transmyocardial Revascularization (TMR). To date, thousands of patients have been treated with the Cardiogenesis TMR technology.

For more information on Cardiogenesis, please visit the Company's website at Cardiogenesis also maintains a website where patients suffering from angina can learn more about the TMR procedure at

SafeHarbor Statement

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the possible effectiveness of the Company's technologies and the effect of such technologies on the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cardiogenesis Reports Third Quarter 2008 Results
2. Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results
3. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
4. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
5. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
6. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
7. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
8. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
9. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
10. Genoptix Announces Participation at the Twentieth Annual Piper Jaffray Healthcare Conference
11. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
Breaking Biology News(10 mins):